Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia

W. Scott Melvin, Jerome A. Johnson, Joann Sparks, Jeffrey T. Innes, E. Christopher Ellison

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background. The long-term prognosis of Zollinger-Ellison Syndrome (ZES) is not well defined. The findings of other endocrinopathies, the need for long-term surveillance, and the role of surgical treatment are controversial. Methods. To help provide more information about these topics the records of 76 patients with ZES were reviewed. Results. Nineteen patients with gastrinoma had multiple endocrine neoplasia (MEN). Fifteen had hyperparathyroidism from 14 years before to 38 years after the diagnosis of ZES. Three patients had pituitary adenomas. The unusual findings of pheochromocytoma were also seen in three patients. Sixteen patients were followed at least 10 years and 12 were followed for more than 20 years. Surgical cure was achieved in only one patient after a 12-year follow-up. The actual 5-, 10-, 15-, and 20-year survival rates of 94%, 75%, 61%, and 58%, respectively, were compared with patients with sporadic ZES with 5-, 10-, 15-, and 20-year survival rates of 62%, 50%, 37%, and 31%, respectively. Conclusions. Multiple endocrinopathies are common but are rarely diagnosed synchronously, mandating life-long surveillance for patients with ZES. Long-term prognosis is goad. Survival is longer for patients with ZES and MEN compared with patients with sporadic ZES. Surgical cure is rare. Surgical excision without a single localized lesion does not seem justified.

Original languageEnglish (US)
Pages (from-to)1183-1188
Number of pages6
JournalSurgery
Volume114
Issue number6
StatePublished - 1993
Externally publishedYes

Fingerprint

Multiple Endocrine Neoplasia
Zollinger-Ellison Syndrome
Survival Rate
Gastrinoma
Hyperparathyroidism
Pituitary Neoplasms
Pheochromocytoma

ASJC Scopus subject areas

  • Surgery

Cite this

Melvin, W. S., Johnson, J. A., Sparks, J., Innes, J. T., & Ellison, E. C. (1993). Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery, 114(6), 1183-1188.

Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. / Melvin, W. Scott; Johnson, Jerome A.; Sparks, Joann; Innes, Jeffrey T.; Ellison, E. Christopher.

In: Surgery, Vol. 114, No. 6, 1993, p. 1183-1188.

Research output: Contribution to journalArticle

Melvin, WS, Johnson, JA, Sparks, J, Innes, JT & Ellison, EC 1993, 'Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia', Surgery, vol. 114, no. 6, pp. 1183-1188.
Melvin WS, Johnson JA, Sparks J, Innes JT, Ellison EC. Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery. 1993;114(6):1183-1188.
Melvin, W. Scott ; Johnson, Jerome A. ; Sparks, Joann ; Innes, Jeffrey T. ; Ellison, E. Christopher. / Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. In: Surgery. 1993 ; Vol. 114, No. 6. pp. 1183-1188.
@article{d1b1774ee86d4614a739b9b66ef3d6a7,
title = "Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia",
abstract = "Background. The long-term prognosis of Zollinger-Ellison Syndrome (ZES) is not well defined. The findings of other endocrinopathies, the need for long-term surveillance, and the role of surgical treatment are controversial. Methods. To help provide more information about these topics the records of 76 patients with ZES were reviewed. Results. Nineteen patients with gastrinoma had multiple endocrine neoplasia (MEN). Fifteen had hyperparathyroidism from 14 years before to 38 years after the diagnosis of ZES. Three patients had pituitary adenomas. The unusual findings of pheochromocytoma were also seen in three patients. Sixteen patients were followed at least 10 years and 12 were followed for more than 20 years. Surgical cure was achieved in only one patient after a 12-year follow-up. The actual 5-, 10-, 15-, and 20-year survival rates of 94{\%}, 75{\%}, 61{\%}, and 58{\%}, respectively, were compared with patients with sporadic ZES with 5-, 10-, 15-, and 20-year survival rates of 62{\%}, 50{\%}, 37{\%}, and 31{\%}, respectively. Conclusions. Multiple endocrinopathies are common but are rarely diagnosed synchronously, mandating life-long surveillance for patients with ZES. Long-term prognosis is goad. Survival is longer for patients with ZES and MEN compared with patients with sporadic ZES. Surgical cure is rare. Surgical excision without a single localized lesion does not seem justified.",
author = "Melvin, {W. Scott} and Johnson, {Jerome A.} and Joann Sparks and Innes, {Jeffrey T.} and Ellison, {E. Christopher}",
year = "1993",
language = "English (US)",
volume = "114",
pages = "1183--1188",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia

AU - Melvin, W. Scott

AU - Johnson, Jerome A.

AU - Sparks, Joann

AU - Innes, Jeffrey T.

AU - Ellison, E. Christopher

PY - 1993

Y1 - 1993

N2 - Background. The long-term prognosis of Zollinger-Ellison Syndrome (ZES) is not well defined. The findings of other endocrinopathies, the need for long-term surveillance, and the role of surgical treatment are controversial. Methods. To help provide more information about these topics the records of 76 patients with ZES were reviewed. Results. Nineteen patients with gastrinoma had multiple endocrine neoplasia (MEN). Fifteen had hyperparathyroidism from 14 years before to 38 years after the diagnosis of ZES. Three patients had pituitary adenomas. The unusual findings of pheochromocytoma were also seen in three patients. Sixteen patients were followed at least 10 years and 12 were followed for more than 20 years. Surgical cure was achieved in only one patient after a 12-year follow-up. The actual 5-, 10-, 15-, and 20-year survival rates of 94%, 75%, 61%, and 58%, respectively, were compared with patients with sporadic ZES with 5-, 10-, 15-, and 20-year survival rates of 62%, 50%, 37%, and 31%, respectively. Conclusions. Multiple endocrinopathies are common but are rarely diagnosed synchronously, mandating life-long surveillance for patients with ZES. Long-term prognosis is goad. Survival is longer for patients with ZES and MEN compared with patients with sporadic ZES. Surgical cure is rare. Surgical excision without a single localized lesion does not seem justified.

AB - Background. The long-term prognosis of Zollinger-Ellison Syndrome (ZES) is not well defined. The findings of other endocrinopathies, the need for long-term surveillance, and the role of surgical treatment are controversial. Methods. To help provide more information about these topics the records of 76 patients with ZES were reviewed. Results. Nineteen patients with gastrinoma had multiple endocrine neoplasia (MEN). Fifteen had hyperparathyroidism from 14 years before to 38 years after the diagnosis of ZES. Three patients had pituitary adenomas. The unusual findings of pheochromocytoma were also seen in three patients. Sixteen patients were followed at least 10 years and 12 were followed for more than 20 years. Surgical cure was achieved in only one patient after a 12-year follow-up. The actual 5-, 10-, 15-, and 20-year survival rates of 94%, 75%, 61%, and 58%, respectively, were compared with patients with sporadic ZES with 5-, 10-, 15-, and 20-year survival rates of 62%, 50%, 37%, and 31%, respectively. Conclusions. Multiple endocrinopathies are common but are rarely diagnosed synchronously, mandating life-long surveillance for patients with ZES. Long-term prognosis is goad. Survival is longer for patients with ZES and MEN compared with patients with sporadic ZES. Surgical cure is rare. Surgical excision without a single localized lesion does not seem justified.

UR - http://www.scopus.com/inward/record.url?scp=0027141420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027141420&partnerID=8YFLogxK

M3 - Article

C2 - 7903006

AN - SCOPUS:0027141420

VL - 114

SP - 1183

EP - 1188

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -